Screener
Veradermics MANE Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Veradermics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Veradermics ’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 5:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001827635-26-000019
| (in thousands) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Direct research and development by program | ||
| VDPHL01 | 17,188 | 9,278 |
| VDMN | 149 | 1,118 |
| VDMC | 26 | 7 |
| VDAA | 1 | 1 |
| Other program candidates and expenses | — | 80 |
| Other unallocated research and development costs | ||
| Personnel expenses (including share-based compensation) | 3,476 | 879 |
Item 1. Condensed Consolidated Financial Statements (
FAQ
- What is Veradermics 's business segments — R&D?
- Veradermics (MANE) reported business segments — R&D of $17.19M in Q1 2026.
- How has Veradermics 's business segments — R&D changed year-over-year?
- Veradermics 's business segments — R&D increased by 50.2% year-over-year, from $11.45M to $17.19M.
- What does business segments — R&D mean?
- This metric represents the total expenditures allocated to the research and development segment, specifically focusing on the advancement of the company's dermatologic therapeutic pipeline. It captures the costs associated with clinical trials, drug discovery, and regulatory activities for novel treatments like VDPHL01 and VDMN. This segment is critical for assessing the company's long-term growth potential and innovation capacity.
Ask your AI about Veradermics 's business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude